StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Cash paid for IPR&D and development milestones by Quarter

Cash paid for IPR&D and development milestones ($M) ($M)

QuarterlyAnnual

Eli Lilly Cash paid for IPR&D and development milestones: $3,282M in Q2 2026, up 2,967.3% from a year earlier. That is the highest of the 17 quarters on record here.

Latest, Q2 2026
3,282
Period ended Jun 30, 2026
Change on a year earlier
+2,967.3%
107 in Q2 2025
History
17 quarters
Since Q1 2016
Sources
12
Documents cited below

Where the Q2 2026 figure comes from

Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Consolidated Statements of Cash Flows.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCash paid for IPR&D and development milestones ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20263,282+2,967.3%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026204-88.4%Form 10-Q (filed 2026-04-30) ↗
Q4 2025Dec 31, 2025424+68.5%Form 10-K (filed 2026-02-12) ↗
Q3 2025Sep 30, 2025720-74.5%Form 10-Q (filed 2025-10-30) ↗
Q2 2025Jun 30, 2025107-39.9%Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 20251,757+1,720.7%Form 10-Q (filed 2026-04-30) ↗
Q4 2024Dec 31, 2024251-56.7%Form 10-K (filed 2026-02-12) ↗
Q3 2024Sep 30, 20242,820-7.0%Form 10-Q (filed 2025-10-30) ↗
Q2 2024Jun 30, 2024178+81.4%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 202496.5-58.9%Form 10-Q (filed 2025-05-01) ↗
Q4 2023Dec 31, 2023580+320.6%Form 10-K (filed 2026-02-12) ↗
Q3 2023Sep 30, 20233,031–Form 10-Q (filed 2024-10-30) ↗
Q2 2023Jun 30, 202398.1–Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023235–Form 10-Q (filed 2024-04-30) ↗
Q4 2022Dec 31, 2022138–Form 10-K (filed 2025-02-19) ↗
Q2 2016Jun 30, 20160–Form 10-Q (filed 2016-07-28) ↗

Cite this data

StockData. (2026). Eli Lilly Cash paid for IPR&D and development milestones ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/iprd-cash-paid

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.